Table 1.
Clinicopathological characteristics of OSCC patients according to statin use in the matched-pair cohort (n = 359, matching variables are highlighted in bold). UICC 7th edition.
| Statin Use | ||||||||
|---|---|---|---|---|---|---|---|---|
| No | Yes | Total | χ2 | |||||
| N | % | N | % | N | % | p | ||
| Sex | Female | 75 | 28.5% | 23 | 24.0% | 98 | 27.3% | 0.391 |
| Male | 188 | 71.5% | 73 | 76.0% | 261 | 72.7% | ||
| Age at diagnosis | 50–59 | 76 | 28.9% | 25 | 26.0% | 101 | 28.1% | 0.840 |
| 60–69 | 106 | 40.3% | 39 | 40.6% | 145 | 40.4% | ||
| 70+ | 81 | 30.8% | 32 | 33.3% | 113 | 31.5% | ||
| CCI | 0 | 72 | 27.4% | 24 | 25.0% | 96 | 26.7% | 0.852 |
| 1 | 62 | 23.6% | 21 | 21.9% | 83 | 23.1% | ||
| 2 | 59 | 22.4% | 21 | 21.9% | 80 | 22.3% | ||
| 3+ | 70 | 26.6% | 30 | 31.3% | 100 | 27.9% | ||
| Positive anamnesis smoking | No | 72 | 27.4% | 28 | 29.2% | 100 | 27.9% | 0.738 |
| Yes | 191 | 72.6% | 68 | 70.8% | 259 | 72.1% | ||
| Positive anamnesis alcohol | No | 82 | 31.2% | 41 | 42.7% | 123 | 34.3% | 0.042 |
| Yes | 181 | 68.8% | 55 | 57.3% | 236 | 65.7% | ||
| Acetylsalicylic acid use | No | 190 | 72.2% | 43 | 44.8% | 233 | 64.9% | <0.001 |
| Yes | 73 | 27.8% | 53 | 55.2% | 126 | 35.1% | ||
| Metformine use | No | 242 | 92.0% | 83 | 86.5% | 325 | 90.5% | 0.111 |
| Yes | 21 | 8.0% | 13 | 13.5% | 34 | 9.5% | ||
| Anatomical site | Upper alveolus and gingiva & Hard palate | 31 | 11.8% | 10 | 10.4% | 41 | 11.4% | 0.860 |
| Tongue | 84 | 31.9% | 29 | 30.2% | 113 | 31.5% | ||
| Buccal mucosa & Lower alveolus and gingiva & Floor of mouth | 148 | 56.3% | 57 | 59.4% | 205 | 57.1% | ||
| UICC stage | I | 83 | 31.6% | 32 | 33.3% | 115 | 32.0% | 0.895 |
| II | 49 | 18.6% | 18 | 18.8% | 67 | 18.7% | ||
| III | 41 | 15.6% | 17 | 17.7% | 58 | 16.2% | ||
| IV | 90 | 34.2% | 29 | 30.2% | 119 | 33.1% | ||
| Tumorsize | T1 | 105 | 39.9% | 40 | 41.7% | 145 | 40.4% | 0.957 |
| T2 | 87 | 33.1% | 29 | 30.2% | 116 | 32.3% | ||
| T3 | 20 | 7.6% | 7 | 7.3% | 27 | 7.5% | ||
| T4 | 51 | 19.4% | 20 | 20.8% | 71 | 19.8% | ||
| Cervical lymph node metastasis | N0 | 172 | 65.4% | 63 | 65.6% | 235 | 65.5% | 0.231 |
| N1 | 34 | 12.9% | 18 | 18.8% | 52 | 14.5% | ||
| N2/3 | 57 | 21.7% | 15 | 15.6% | 72 | 20.1% | ||
| Extranodal spread | No | 60 | 22.8% | 22 | 22.9% | 82 | 22.8% | 0.936 |
| Yes | 31 | 11.8% | 10 | 10.4% | 41 | 11.4% | ||
| not applicable | 172 | 65.4% | 64 | 66.7% | 236 | 65.7% | ||
| Grading | G1 | 25 | 9.5% | 7 | 7.3% | 32 | 8.9% | 0.763 |
| G2 | 186 | 70.7% | 68 | 70.8% | 254 | 70.8% | ||
| G3/4 | 52 | 19.8% | 21 | 21.9% | 73 | 20.3% | ||
| Lymphatic invasion | L0 | 217 | 82.5% | 77 | 80.2% | 294 | 81.9% | 0.616 |
| L1 | 46 | 17.5% | 19 | 19.8% | 65 | 18.1% | ||
| Vascular invasion | V0 | 252 | 95.8% | 93 | 96.9% | 345 | 96.1% | 0.647 |
| V1 | 11 | 4.2% | 3 | 3.1% | 14 | 3.9% | ||
| Adjuvant therapy | No | 153 | 58.2% | 65 | 67.7% | 218 | 60.7% | 0.054 |
| Radiotherapy | 80 | 30.4% | 17 | 17.7% | 97 | 27.0% | ||
| Radiochemotherapy | 30 | 11.4% | 14 | 14.6% | 44 | 12.3% | ||
| Total | 263 | 100.0% | 96 | 100.0% | 359 | 100.0% | ||
Abbreviations: CCI: Charlson comorbidity index; UICC: Union for International Cancer Control; HR: hazard ratio; CI: confidence interval; OAS: overall survival; RFS: recurrence-free survival.